Sarah Rybowski

475 total citations
23 papers, 312 citations indexed

About

Sarah Rybowski is a scholar working on Public Health, Environmental and Occupational Health, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Sarah Rybowski has authored 23 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Public Health, Environmental and Occupational Health, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Sarah Rybowski's work include Reproductive Health and Contraception (12 papers), Advanced Breast Cancer Therapies (10 papers) and Maternal and fetal healthcare (7 papers). Sarah Rybowski is often cited by papers focused on Reproductive Health and Contraception (12 papers), Advanced Breast Cancer Therapies (10 papers) and Maternal and fetal healthcare (7 papers). Sarah Rybowski collaborates with scholars based in United States, Germany and Sweden. Sarah Rybowski's co-authors include Kristina Gemzell‐Danielsson, Dan Apter, K. Rosén, Anita L. Nelson, Brian Hauck, Thomas Schmelter, Anne Szarewski, Eeva Lukkari‐Lax, Paula Briggs and Marjo Tuppurainen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Sarah Rybowski

22 papers receiving 292 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah Rybowski United States	8	229	111	76	65	58	23	312
Ailsa Gebbie United Kingdom	11	179 0.8×	74 0.7×	185 2.4×	15 0.2×	113 1.9×	37	410
Stinne Holm Bergholdt Denmark	8	210 0.9×	71 0.6×	109 1.4×	24 0.4×	12 0.2×	12	375
A. Palumbo Italy	9	65 0.3×	49 0.4×	33 0.4×	13 0.2×	56 1.0×	14	249
Carina Nord Norway	8	64 0.3×	94 0.8×	76 1.0×	46 0.7×	6 0.1×	11	340
Cordula Franz Germany	7	100 0.4×	53 0.5×	46 0.6×	10 0.2×	79 1.4×	11	282
Blair McNamara United States	9	60 0.3×	42 0.4×	76 1.0×	29 0.4×	86 1.5×	34	238
A. Marsh Poulson United States	10	171 0.7×	64 0.6×	185 2.4×	16 0.2×	78 1.3×	16	344
Harika Bodur Türkiye	8	127 0.6×	199 1.8×	58 0.8×	15 0.2×	203 3.5×	17	357
Nathaniel Henry United Kingdom	6	215 0.9×	161 1.5×	50 0.7×	20 0.3×	69 1.2×	9	346
Samuel Shapiro United States	7	67 0.3×	23 0.2×	106 1.4×	37 0.6×	43 0.7×	7	278

Countries citing papers authored by Sarah Rybowski

Since Specialization

Citations

This map shows the geographic impact of Sarah Rybowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Rybowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Rybowski more than expected).

Fields of papers citing papers by Sarah Rybowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Rybowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Rybowski. The network helps show where Sarah Rybowski may publish in the future.

Co-authorship network of co-authors of Sarah Rybowski

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Rybowski. A scholar is included among the top collaborators of Sarah Rybowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Rybowski. Sarah Rybowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gathirua‐Mwangi, Wambui G., Holly Martin, Dan He, et al.. (2024). Real-world outcomes in patients with brain metastases secondary to HR+/HER2− MBC treated with abemaciclib and local intracranial therapy. The Oncologist. 30(8). 1 indexed citations

Ring, Alistair, Meghan Karuturi, Emily Nash Smyth, et al.. (2023). Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice. Advances in Therapy. 40(5). 2515–2523. 3 indexed citations

Ring, Alistair, Meghan Karuturi, Emily Nash Smyth, et al.. (2023). Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice. Drugs - Real World Outcomes. 10(4). 589–603. 2 indexed citations

Smyth, Emily Nash, et al.. (2022). Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib. Drugs - Real World Outcomes. 9(4). 681–693. 10 indexed citations

Price, Gregory L., Lavanya Sudharshan, Paula D. Ryan, et al.. (2022). Real world incidence and management of adverse events in patients with HR+, HER2− metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting. Current Medical Research and Opinion. 38(8). 1319–1331. 12 indexed citations

Vidal, Gregory A., Gebra Cuyún Carter, Adrienne M. Gilligan, et al.. (2021). Development of a Prognostic Factor Index Among Women With HR+/HER2− Metastatic Breast Cancer in a Community Oncology Setting. Clinical Breast Cancer. 21(4). 317–328.e7. 2 indexed citations

Smyth, Emily Nash, et al.. (2021). Abstract PS10-46: Real-world patient characteristics, utilization patterns, and outcomes of US patients with HR+/HER2- metastatic breast cancer treated with abemaciclib. Cancer Research. 81(4_Supplement). PS10–46. 1 indexed citations

Ryan, Paula D., Gregory L. Price, Gebra Cuyún Carter, et al.. (2021). HSR21-051: Treatment Outcomes Among HR+/HER2- Advanced/Metastatic Breast Cancer Patients Receiving CDK 4 & 6 Inhibitors in a United States Clinical Practice Setting. Journal of the National Comprehensive Cancer Network. 19(3.5). HSR21–51. 1 indexed citations

Carter, Gebra Cuyún, Kristin M. Sheffield, Anala Gossai, et al.. (2020). Abstract P2-08-12: Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2- metastatic breast cancer. Cancer Research. 80(4_Supplement). P2–8. 7 indexed citations

10.

Apter, Dan, Paula Briggs, Marjo Tuppurainen, et al.. (2016). A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Fertility and Sterility. 106(1). 151–157.e5. 39 indexed citations

11.

Borgatta, Lynn, Kai J. Bühling, Sarah Rybowski, Katrin Roth, & K. Rosén. (2016). A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age. The European Journal of Contraception & Reproductive Health Care. 21(5). 372–379. 9 indexed citations

12.

Gemzell‐Danielsson, Kristina, Dan Apter, Brian Hauck, et al.. (2015). The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial. PLoS ONE. 10(9). e0135309–e0135309. 39 indexed citations

13.

Gemzell‐Danielsson, Kristina, Kai J. Bühling, Eeva Lukkari‐Lax, et al.. (2014). A multicenter, open-label, single-arm study exploring the safety of a new 13.5 mg total dose levonorgestrel intrauterine contraceptive system in postmenarcheal adolescents. Fertility and Sterility. 102(3). e12–e13. 2 indexed citations

14.

Borgatta, Lynn, Katrin Roth, Sarah Rybowski, & K. Rosén. (2014). A randomized phase III study comparing a new 13.5 mg levonorgestrel intrauterine contraceptive system with a combined oral contraceptive: analysis of efficacy and bleeding profiles. Fertility and Sterility. 102(3). e143–e143. 1 indexed citations

15.

Gemzell‐Danielsson, Kristina, et al.. (2014). A phase III single-arm study of a new 13.5 mg levonorgestrel intrauterine contraceptive system in postmenarcheal adolescents: an evaluation of efficacy, bleeding, user satisfaction, and placement. Fertility and Sterility. 102(3). e141–e142. 3 indexed citations

16.

Tuppurainen, M., et al.. (2014). A 12-month multicenter, randomized phase III study comparing a 13.5 mg levonorgestrel intrauterine contraceptive system with the etonogestrel subdermal contraceptive implant in women aged 18–35 years. Fertility and Sterility. 102(3). e142–e142. 7 indexed citations

17.

Borgatta, Lynn, Katrin Roth, Sarah Rybowski, & K. Rosén. (2014). A multicenter, randomized phase III study comparing a 13.5 mg levonorgestrel intrauterine contraceptive system with a combined oral contraceptive: analysis of user satisfaction and safety. Fertility and Sterility. 102(3). e12–e12.

18.

Nelson, Anita L., Dan Apter, Brian Hauck, et al.. (2013). Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems. Obstetrics and Gynecology. 122(6). 1205–1213. 106 indexed citations

19.

Szarewski, Anne, et al.. (2012). Women's attitudes towards monthly bleeding: Results of a global population-based survey. The European Journal of Contraception & Reproductive Health Care. 17(4). 270–283. 34 indexed citations

20.

Nelson, Anita L., Dan Apter, Brian Hauck, et al.. (2012). A global, randomized, phase III, pearl index study comparing the efficacy and safety of two low-dose levonorgestrel-releasing intrauterine systems (LNG-IUSS) in nulliparous and parous women. Fertility and Sterility. 98(3). S5–S5. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact